Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel Added to Russell 3000® Index
CAMBRIDGE, Mass. , June 25, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has been added to the Russell 3000 ® Index as part of the annual Russell U.S.
View HTML
Toggle Summary Vericel Announces Appointment of Jonathan Hopper as Chief Medical Officer
CAMBRIDGE, Mass. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the appointment of Jonathan Hopper as Chief Medical Officer. Dr.
View HTML
Toggle Summary Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common
View HTML
Toggle Summary Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it intends to offer and sell, subject to market and other conditions, 3,750,000 shares of its common
View HTML
Toggle Summary Vericel Corporation Prices $65 Million Public Offering of Common Stock
CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common
View HTML
Toggle Summary Vericel Initiates Collaboration with Innovative Cellular Therapeutics
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its License Agreement with
View HTML
Toggle Summary Vericel Reports First Quarter 2018 Financial Results
Record First Quarter Revenues of $18.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial
View HTML
Toggle Summary Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance
Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016 Positive Operating and Net Income Reported for the Fourth Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
View HTML
Toggle Summary Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
CAMBRIDGE, Mass. , March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI ® (autologous cultured chondrocytes on porcine collagen
View HTML
Toggle Summary Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second
View HTML
Toggle Summary Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results
View HTML
Toggle Summary Vericel to Host Analyst and Investor Day on April 11, 2018
CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m.
View HTML
Toggle Summary Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass. , March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel , chief financial officer and VP of corporate development, will present the latest
View HTML
Toggle Summary Vericel to Present at Multiple Upcoming Conferences
CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences: Nick Colangelo, president and CEO, will present at
View HTML
Toggle Summary Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
CAMBRIDGE, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 13th Annual
View HTML
Toggle Summary Vericel to Present at the 17th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. , March 13, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 17 th Annual
View HTML
Toggle Summary Vericel to Present at the 20th Annual Needham Growth Conference
CAMBRIDGE, Mass. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference
CAMBRIDGE, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 38th Annual
View HTML
Toggle Summary Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 6 th Annual
View HTML
Toggle Summary Vericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 7 th Annual
View HTML
Toggle Summary Vericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the BIO CEO &
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum
CAMBRIDGE, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the Canaccord
View HTML
Toggle Summary Vericel to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. , May 25, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the Jefferies 2018
View HTML
Toggle Summary Vericel to Report First-Quarter 2018 Financial Results on May 8, 2018
CAMBRIDGE, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2018 financial results and
View HTML
Toggle Summary Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
CAMBRIDGE, Mass. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial
View HTML
Toggle Summary Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
CAMBRIDGE, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2018 financial results and
View HTML
Toggle Summary Vericel to Report Third-Quarter 2018 Financial Results on November 6, 2018
CAMBRIDGE, Mass. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2018 financial results and
View HTML
Toggle Summary World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ Campaign
Campaign Aims to Empower Patients with Knee Pain to Seek Treatment CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that world champion swimmer,
View HTML